Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Non-Current Liabilities (2016 - 2026)

Sunshine Biopharma filings provide 9 years of Total Non-Current Liabilities readings, the most recent being $596785.0 for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 19.86% to $596785.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $596785.0, a 19.86% decrease, with the full-year FY2025 number at $596785.0, down 19.86% from a year prior.
  • Total Non-Current Liabilities hit $596785.0 in Q4 2025 for Sunshine Biopharma, down from $636708.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.9 million in Q4 2021 to a low of $489027.0 in Q3 2024.
  • Median Total Non-Current Liabilities over the past 5 years was $638295.0 (2023), compared with a mean of $715793.0.
  • Biggest five-year swings in Total Non-Current Liabilities: crashed 63.93% in 2022 and later soared 38.09% in 2025.
  • Sunshine Biopharma's Total Non-Current Liabilities stood at $1.9 million in 2021, then crashed by 63.93% to $685264.0 in 2022, then decreased by 14.23% to $587764.0 in 2023, then grew by 26.7% to $744724.0 in 2024, then decreased by 19.86% to $596785.0 in 2025.
  • The last three reported values for Total Non-Current Liabilities were $596785.0 (Q4 2025), $636708.0 (Q3 2025), and $706530.0 (Q2 2025) per Business Quant data.